The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking

CI-581a during weeks 1 and 6 at 0.71 mg/kg

CI-581b during weeks 1 and 6 at 0.0125 mg/kg

MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).

MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).